(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation…
(IN BRIEF) AstraZeneca's new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review…